Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression.
Inactivating mutations in the p53 tumor suppressor gene occur often in the progression of human cancers. p53 inhibits the outgrowth of nascent cancer cells through anti-proliferative actions (including induction of apoptosis or senescence). To test p53 tumor suppressor functions in a novel experimental context, we somatically deleted both p53 alleles in multiple tissues of mice at various ages. Mice homozygously deleted for p53 at 3 months of age showed a longer tumor latency compared to mice deleted for p53 at 6 and 12 months of age. These results are consistent with a model in which tissues accumulate oncogenically activated cells with age and these are held in check by wildtype p53. We also deleted p53 before, concurrent with, and after treatment of mice with ionizing radiation (IR). The absence or presence of p53 during IR treatment had no effect on radiation-induced lymphoma latency, confirming that the immediate p53 damage response was irrelevant for cancer prevention. Even the presence of wildtype p53 for up to four weeks post-IR provided no protection against early lymphoma incidence, indicating that long term maintenance of functional p53 is critical for preventing the emergence of a cancer. These experiments indicate that sustained p53 anti-oncogenic function acts as a final or near final line of defense preventing progression of oncogenically activated cells to malignant tumors.
Hinkal
George
G
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Parikh
Neha
N
Donehower
Lawrence A
LA
D000375:Aging / Q000473:pathology*; D000483:Alleles; D000818:Animals; D017209:Apoptosis; D018450:Disease Progression; D017353:Gene Deletion; D016158:Genes, p53; D006720:Homozygote; D008223:Lymphoma / Q000235:genetics / Q000473:pathology*; D051379:Mice; D009381:Neoplasms, Radiation-Induced / Q000235:genetics / Q000473:pathology*; D013629:Tamoxifen / Q000008:administration & dosage
D013629:Tamoxifen
Nature. 2006 Sep 14;443(7108):214-7
16957739
Mutagenesis. 1998 Mar;13(2):109-14
9568581
Curr Opin Genet Dev. 2000 Feb;10(1):81-93
10679386
Methods Mol Biol. 2003;234:29-49
12824523
Mutat Res. 2005 Aug 25;576(1-2):4-21
16038709
Physiol Genomics. 2007 Sep 19;31(1):32-41
17456738
Toxicol Pathol. 2001;29 Suppl:147-54
11695551
Nature. 2007 Jul 19;448(7151):375-9
17637672
Nucleic Acids Res. 2003 Feb 15;31(4):e12
12582257
Cell. 1996 Oct 18;87(2):159-70
8861899
Cell. 1997 Feb 7;88(3):323-31
9039259
EMBO J. 2002 Nov 15;21(22):6225-35
12426394
Science. 1996 Mar 22;271(5256):1744-7
8596939
Nat Genet. 1994 Sep;8(1):66-9
7987394
Cancer Cell. 2007 Oct;12(4):303-12
17936556
Genes Dev. 2004 Feb 1;18(3):306-19
14871929
Genes Dev. 1995 Apr 1;9(7):882-95
7705663
Cancer Res. 1995 Sep 1;55(17):3883-9
7641208
Nat Rev Cancer. 2007 Sep;7(9):645-58
17687385
Br J Cancer. 1998;77(2):243-52
9460995
Mutat Res. 2000 Sep 18;452(2):149-62
11024475
Oncogene. 2001 Apr 5;20(15):1803-15
11313928
Curr Opin Genet Dev. 2007 Feb;17(1):66-70
17208429
Genes Dev. 2000 Apr 15;14(8):994-1004
10783170
Oncogene. 1994 Feb;9(2):603-9
8290271
Cell. 2006 Oct 20;127(2):265-75
17055429
Semin Cancer Biol. 1994 Jun;5(3):177-86
7948946
Cell. 2002 Jan 25;108(2):135-44
11832204
Nature. 2002 Jan 3;415(6867):45-53
11780111
Carcinogenesis. 2001 Jun;22(6):839-49
11375888
Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16633-8
17921246
Oncogene. 1997 Sep;15(11):1295-302
9315097
Trends Cell Biol. 2008 May;18(5):244-52
18406616
Genetics. 2005 Jan;169(1):265-74
15466429
Mech Ageing Dev. 2009 Apr;130(4):262-71
19396980